Myriad Genetics Company Profile (NASDAQ:MYGN)

About Myriad Genetics

Myriad Genetics logoMyriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing, or assess a patient's risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Research Services
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MYGN
  • CUSIP: 62855J10
Key Metrics:
  • Previous Close: $19.72
  • 50 Day Moving Average: $20.54
  • 200 Day Moving Average: $28.92
  • 52-Week Range: $17.66 - $46.24
  • Trailing P/E Ratio: 11.53
  • Foreward P/E Ratio: 17.00
  • P/E Growth: 3.52
  • Market Cap: $1.36B
  • Outstanding Shares: 69,134,000
  • Beta: 0.54
  • Net Margins: 14.98%
  • Return on Equity: 16.06%
  • Return on Assets: 14.03%
  • Current Ratio: 4.35%
  • Quick Ratio: 3.82%
Additional Links:
Companies Related to Myriad Genetics:

Analyst Ratings

Consensus Ratings for Myriad Genetics (NASDAQ:MYGN) (?)
Ratings Breakdown: 3 Sell Ratings, 8 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $30.64 (55.39% upside)

Analysts' Ratings History for Myriad Genetics (NASDAQ:MYGN)
DateFirmActionRatingPrice TargetDetails
10/10/2016Bank of America Corp.Reiterated RatingSellView Rating Details
10/10/2016Barclays PLCReiterated RatingEqual Weight$24.00 -> $22.00View Rating Details
10/10/2016Ladenburg ThalmannDowngradeNeutral -> Sell$16.00View Rating Details
8/21/2016Wells Fargo & Co.UpgradeMarket Perform -> OutperformView Rating Details
8/11/2016Jefferies GroupLower Price TargetHold$34.00 -> $20.00View Rating Details
8/11/2016StephensSet Price TargetBuy$30.00View Rating Details
8/10/2016Morgan StanleyLower Price TargetUnderweight$25.00 -> $21.00View Rating Details
8/10/2016GabelliDowngradeBuy -> Hold$46.00 -> $32.00View Rating Details
8/10/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$47.00 -> $22.00View Rating Details
8/10/2016MizuhoLower Price TargetNeutral$34.00 -> $22.00View Rating Details
5/4/2016Leerink SwannReiterated RatingMarket Perform$44.00 -> $41.00View Rating Details
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00View Rating Details
3/23/2016Goldman Sachs Group Inc.Boost Price Target$40.00View Rating Details
2/3/2016Deutsche Bank AGReiterated RatingBuy$52.00 -> $51.00View Rating Details
1/7/2016Cowen and CompanyBoost Price Target$40.00View Rating Details
9/20/2015William BlairReiterated RatingBuyView Rating Details
8/12/2015JMP SecuritiesLower Price TargetMarket Outperform$46.00 -> $40.00View Rating Details
5/28/2015Credit Suisse Group AGReiterated RatingUnderperformView Rating Details
5/7/2015Cantor FitzgeraldReiterated RatingBuy$43.00View Rating Details
2/4/2015Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details
(Data available from 10/22/2014 forward)


Earnings History for Myriad Genetics (NASDAQ:MYGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q416$0.38$0.36$187.95 million$186.50 millionViewN/AView Earnings Details
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details
11/4/2014Q115$0.32$0.25$175.00 million$168.84 millionViewListenView Earnings Details
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details
5/6/2014Q314$0.45$0.48$175.23 million$182.92 millionViewListenView Earnings Details
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details
8/14/2012$0.34$0.34ViewN/AView Earnings Details
5/1/2012$0.32$0.34ViewN/AView Earnings Details
1/31/2012$0.31$0.33ViewN/AView Earnings Details
11/1/2011$0.27$0.29ViewN/AView Earnings Details
8/9/2011$0.29$0.30ViewN/AView Earnings Details
5/3/2011$0.25$0.31ViewN/AView Earnings Details
1/27/2011$0.26$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Myriad Genetics (NASDAQ:MYGN)
Current Year EPS Consensus Estimate: $1.04 EPS
Next Year EPS Consensus Estimate: $1.16 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.37$0.38$0.38
Q2 20164$0.41$0.43$0.42
Q3 20161$0.42$0.42$0.42
Q4 20162$0.36$0.45$0.41
Q1 20173$0.25$0.42$0.31
Q2 20173$0.29$0.46$0.35
Q3 20173$0.27$0.43$0.32
Q4 20173$0.25$0.38$0.29
(Data provided by Zacks Investment Research)


Dividend History for Myriad Genetics (NASDAQ:MYGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Myriad Genetics (NASDAQ:MYGN)
Insider Ownership Percentage: 6.20%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/12/2016John T HendersonDirectorSell30,000$20.49$614,700.00View SEC Filing  
8/19/2016Mark Christopher CaponeInsiderBuy10,000$21.24$212,400.00View SEC Filing  
8/12/2016Ralph L McdadeInsiderBuy1,000$21.49$21,490.00View SEC Filing  
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.19View SEC Filing  
4/6/2016Gary A KingVPSell15,000$39.03$585,450.00View SEC Filing  
4/1/2016Gary A KingVPSell15,000$38.12$571,800.00View SEC Filing  
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.00View SEC Filing  
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.00View SEC Filing  
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.00View SEC Filing  
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.00View SEC Filing  
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.00View SEC Filing  
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.32View SEC Filing  
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.60View SEC Filing  
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.30View SEC Filing  
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.00View SEC Filing  
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.42View SEC Filing  
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.58View SEC Filing  
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.00View SEC Filing  
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.00View SEC Filing  
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.00View SEC Filing  
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.80View SEC Filing  
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.20View SEC Filing  
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00View SEC Filing  
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.00View SEC Filing  
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.00View SEC Filing  
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.00View SEC Filing  
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.00View SEC Filing  
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.00View SEC Filing  
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.50View SEC Filing  
2/24/2014Gary KingVPSell20,000$38.00$760,000.00View SEC Filing  
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.00View SEC Filing  
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88View SEC Filing  
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.96View SEC Filing  
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  
2/18/2014Gary KingVPSell25,000$34.74$868,500.00View SEC Filing  
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  
2/14/2014Richard MarshVPSell20,960$31.50$660,240.00View SEC Filing  
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18View SEC Filing  
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.00View SEC Filing  
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.00View SEC Filing  
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.00View SEC Filing  
11/8/2013James EvansCFOSell8,072$26.50$213,908.00View SEC Filing  
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.00View SEC Filing  
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Myriad Genetics (NASDAQ:MYGN)
DateHeadline logoMyriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality ... (NASDAQ:MYGN) - October 22 at 5:54 PM logoMyriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services ... - GlobeNewswire (press release) (NASDAQ:MYGN) - October 21 at 6:21 PM logoMyriad Genetics (MYGN), AmerisourceBergen's (ABC) ION Solutions Enter Cancer Tests, Services Relationship - (NASDAQ:MYGN) - October 21 at 9:45 AM logoMyriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nation’s Largest Network of Community Oncologists (NASDAQ:MYGN) - October 21 at 9:45 AM logoMyriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nation's Largest Network of Community Oncologists (NASDAQ:MYGN) - October 21 at 9:45 AM
News IconNoteworthy Analyst Ratings of Two Stocks: Myriad Genetics, Inc ... - The Voice Registrar (NASDAQ:MYGN) - October 20 at 12:02 PM
News IconNew York State Teachers Retirement System Holds Position in Myriad Genetics Inc. (MYGN) - DailyQuint (NASDAQ:MYGN) - October 20 at 12:02 PM logoMyriad to Announce Fiscal First-Quarter 2017 Financial Results on November 1 (NASDAQ:MYGN) - October 20 at 12:02 PM logoMyriad Genetics Teams Up with Project BioEYES to Advance STEM Education in Utah - GlobeNewswire (press release) (NASDAQ:MYGN) - October 19 at 6:39 PM logoMyriad Genetics (MYGN) Will Present Data on Four New Studies at ... - (NASDAQ:MYGN) - October 18 at 11:37 AM logoOption Bears Aren't Buying the Myriad Genetics, Inc. (MYGN) Bounce - Schaeffers Research (blog) (NASDAQ:MYGN) - October 18 at 11:37 AM logoMyriad Genetics Teams Up with Project BioEYES to Advance STEM Education in Utah (NASDAQ:MYGN) - October 18 at 11:37 AM logoOption Bears Aren't Buying the Myriad Genetics, Inc. (MYGN) Bounce (NASDAQ:MYGN) - October 17 at 6:12 PM logoMyriad Will Present New Data on Its Variant Classification Program at the ASHG Annual Meeting (NASDAQ:MYGN) - October 17 at 11:27 AM logoBenjamin Graham's 'Intelligent Investing' Approach: 3 Stocks To Buy (NASDAQ:MYGN) - October 17 at 11:27 AM
News IconShare Value Diminishing Over Past Month: Myriad Genetics, Inc. (NASDAQ:MYGN) - CSZ News (NASDAQ:MYGN) - October 15 at 5:56 PM
News IconBuyers and Sellers Alert – Myriad Genetics, Inc.'s (MYGN) | Hot ... - Hot Stocks Point (NASDAQ:MYGN) - October 15 at 5:56 PM
News IconIt's Earnings Time: What to Do with Myriad Genetics, Inc. (NASDAQ:MYGN) Stock - The Voice Registrar (NASDAQ:MYGN) - October 15 at 5:56 PM
News IconLadenburg Thalmann Downgrades Rating On Myriad Genetics, Inc. (MYGN) (NASDAQ:MYGN) - October 14 at 9:36 AM
News IconMyriad Genetics Inc. (MYGN) Stock Rating Reaffirmed by Bank of America Corp (NASDAQ:MYGN) - October 14 at 9:36 AM logoTraders Recap: Myriad Genetics, Inc. (MYGN), ING Groep N.V. (ING), UBS Group AG (UBS) - iStreetWire (NASDAQ:MYGN) - October 13 at 9:54 AM logoMyriad Genetics, Inc. (NASDAQ:MYGN) Sales Estimate At $1009.5 - Investor Newswire (NASDAQ:MYGN) - October 12 at 6:17 PM
News IconEarnings Estimates Analysis: Myriad Genetics, Inc. (NASDAQ:MYGN) - TRA (NASDAQ:MYGN) - October 12 at 11:38 AM logoMyriad Genetics Reports Encouraging myChoice HRD Data (NASDAQ:MYGN) - October 12 at 11:38 AM logoWhy Bristol-Myers Squibb, Myriad Genetics, and Twilio Slumped Today (NASDAQ:MYGN) - October 10 at 6:52 PM logoWill Insiders Be Tempted To Buy More MYGN At The New 52-Week Low? (NASDAQ:MYGN) - October 10 at 5:54 PM logoWhy Myriad Genetics, Inc. Got Crushed Today (NASDAQ:MYGN) - October 10 at 5:54 PM logoMyriad Genetics eases 12% on potential soft demand for companion diagnostics in cancer (NASDAQ:MYGN) - October 10 at 4:52 PM logoWhat TESARO's Phase 3 NOVA Results Mean For Myriad Genetics (NASDAQ:MYGN) - October 10 at 3:09 PM logoMyriad Genetics (MYGN) Announces Strong Data from myChoice HRD Test in Ovarian Cancer (TSRO) (NASDAQ:MYGN) - October 10 at 11:00 AM
News IconMyriad Genetics, Inc.: Myriad's myChoice® HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib (NASDAQ:MYGN) - October 8 at 10:47 AM logoMYRIAD GENETICS INC (NASDAQ:MYGN) - October 8 at 10:47 AM logoMyriad's myChoice® HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib (NASDAQ:MYGN) - October 8 at 10:47 AM logoMyriad Genetics hails results of ovarian cancer test (NASDAQ:MYGN) - October 8 at 10:47 AM logoMyriad Announces Four Poster Presentations at the 2016 ESMO Annual Meeting (NASDAQ:MYGN) - October 7 at 11:26 AM logoMyriad Announces Four Poster Presentations at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting (NASDAQ:MYGN) - October 7 at 11:26 AM logoInvestor's Watch List Nokia Corp (ADR) (NYSE:NOK), Myriad Genetics, Inc. (NASDAQ:MYGN) - Wall Street 24 (NASDAQ:MYGN) - October 6 at 6:08 PM
News IconNotable Runner: Institutional Investors Lead Shift in Myriad Genetics Inc (NASDAQ:MYGN) Sentiment - Post News (NASDAQ:MYGN) - October 6 at 6:08 PM logoETF’s with exposure to Myriad Genetics, Inc. : October 6, 2016 (NASDAQ:MYGN) - October 6 at 11:49 AM logoCommit To Buy Myriad Genetics At $17, Earn 10.4% Annualized Using Options (NASDAQ:MYGN) - October 5 at 6:12 PM logo7:06 am Myriad Genetics announces that the US Oncology Network selected Myriad Genetic Laboratories as its preferred provider laboratory for hereditary cancer testing (NASDAQ:MYGN) - October 4 at 11:03 AM logoThe US Oncology Network Selects Myriad Genetics as Preferred Provider for Hereditary Cancer Testing (NASDAQ:MYGN) - October 4 at 11:03 AM
News IconMyriad Genetics, Incorporated (NASDAQ:MYGN) To Report September 2016 Results - The Voice Registrar (NASDAQ:MYGN) - October 3 at 5:57 PM logoCORRECTED: Crescendo Bioscience Announces Four Poster Presentations at the American College of Rheumatology 2016 Annual Meeting (NASDAQ:MYGN) - October 3 at 5:56 PM logoCrescendo Bioscience Announces Four Poster Presentations at the American College of Rheumatology 2016 Annual Meeting (NASDAQ:MYGN) - October 3 at 10:54 AM
News IconMyriad Genetics, Inc. (NASDAQ:MYGN) Analytical Analysis - Newburgh Press (NASDAQ:MYGN) - October 2 at 5:33 PM
News IconServices Stocks To Look Out For: Myriad Genetics, Inc. (MYGN), Norwegian Cruise Line Holdings Ltd. (NCLH) - The Independent Republic (NASDAQ:MYGN) - September 30 at 6:25 PM logoMyriad Appoints Chip Parkinson as EVP for Reimbursement Strategy - GlobeNewswire (press release) (NASDAQ:MYGN) - September 29 at 6:17 PM logoMyriad Appoints Chip Parkinson as EVP for Reimbursement Strategy (NASDAQ:MYGN) - September 29 at 11:26 AM logo3 Signs Invitae's Best Days Are Ahead (NASDAQ:MYGN) - September 28 at 6:01 PM


Myriad Genetics (NASDAQ:MYGN) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by Staff